ClinicalTrials.gg
RecruitingNCT03984253Updated Nov 2, 2026

Swiss Severe Asthma Register

An observational study in Severe Asthma, sponsored by Prof. Dr. Jörg Leuppi. Recruiting at 10 sites in Switzerland. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Prof. Dr. Jörg Leuppi · Observational

How we know

From the registry’s dates

  • Started May 2019; still recruiting 7 years 6 months later.
Updated Nov 2, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Asthma with a site in Switzerland — 6 open to participants now, 6 under way, none of them phase 3. Asthma · Switzerland.

Started
2019
the only one that year
Observational
9 of 29
3 open now
Registered
20th of 29
by date

Among the 29 studies in Asthma with a site in Switzerland, this one is the only one that started in 2019, is one of 9 observational ones, and was the 20th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 29 studies in Asthma with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Asthma with a site in Switzerland, or all of them as a file.
02

Study summary

Asthma is one of the most common chronic diseases. Asthma is characterized by chronic airway inflammation and associated with airway hyperresponsiveness and reversible airflow obstruction. The variability of airway obstruction is triggered by different factors that lead to a variety of different asthma phenotypes and subtypes. The various classification options for asthma (e.g. severity, by the predominantly existing inflammation or according to triggers), reflect its heterogeneity.

Despite improved therapeutic methods, the prevalence and morbidity of asthma has increased worldwide in the last years. Asthma is a serious and growing global health problem with around 300 million people affected, independent of age or sex. Estimated 250'000 people die prematurely each year due to their asthma.

Based on the SAPALDIA-study, the prevalence of Asthma in Switzerland is approximately 2-8%. Asthma is considered as a major factor in healthcare cost with up to CHF 1.2 billion per year. Asthma is not only a financial burden to a system; it affects the individual Quality of life negatively. Often health care professionals and patients underestimate the severity of the disease and overestimate asthma control. Severe asthma should not be equated with uncontrolled asthma. To reach a satisfying asthma control numerous factors need to be taken into consideration. Severe asthma is often associated with a high risk of frequent, severe exacerbations, which can even lead to death.

Several severe asthma cohorts and registries already exists and are reported in the literature. The aim of such registries is in general data collection and a better understanding of the disease. So far, most epidemiological studies on severe asthma are cross-sectional with no follow up measures. Only a few studies did repeated measures using the same methods.

Approximately 5% of all Asthma Patients suffers from severe asthma. These patients require systematic assessment and specialist care in dedicated respiratory centres. These centres have a key role in improving the outcome for severe asthma patients. At the same time they act as gatekeepers to ensure appropriate access to new, expensive therapies, this includes antibody treatment and interventional methods such as thermoplasty. These treatments require careful monitoring. It is important to ensure that they are given to the right population. Special assessment to monitor the efficacy and to prevent inappropriate prescribing, exposure of patients to unnecessary risks and excessive costs is indicated.

For all the mentioned reasons a Swiss Severe Asthma Register and a collaboration with an already existing register is needed to prospectively collect data about severe asthma in Switzerland.

Read the detailed description

The overall objective is to establish a clinical register for patients with severe asthma. Since the number of patients with severe asthma at a single center is usually low, it will be important to collect data in a multi-center system to optimize the diagnostic evaluation and treatment of patients with severe asthma. So far, there is little reliable information about the frequency, phenotype and therapy of patients with severe asthma. The construction of a clinical register should close this gap. The primary objective is to show changes in symptoms control during follow up period and at study end by using the Asthma Control Test (ACT). Secondary endpoints are to collect data to better understand asthma's natural history in patients with severe asthma. The examination will be based on the assessment of the parameters specified under "outcomes".

Patients presenting to participating study center (pulmonologists in private practice or in pulmonary departments in hospital within Switzerland) with severe asthma will be asked to take part in this study when corresponding to the eligibility criteria. All patients with severe asthma will be included in the register only after detailed information and written consent. After four months (for specific therapies) and after 12 months, patients should be re-evaluated for up to 15 years. These follow-up data will also be recorded in the register. During the follow-up visits, the same parameters will be collected as during the initial Baselineexamination (some parameters will be omitted, for example, therapy received or requested for the defined period of the last 12 months, etc.). Severe asthma patients receiving a new specific therapy, e.g. obtained with antibodies, but who cannot be included in the register with the complete parameter profile due to time or capacity reasons of the centers, should be recorded at least with defined basic data and a reduced number of parameters in the register. These parameters include according to the specific asthma approved specific therapies, socio-demographic data, lung function values, laboratory values, parameters of asthma control, smoking status and add-on- therapy. This should make it possible to record a subgroup of severe asthmatics that are suitable for antibody therapy and at the same time offer the attending physician the opportunity to adequately document these complex and expensive therapies by recording the defined parameters. In these patients, an evaluation of the therapy response should be carried out after four months and documented in the register. Thereafter, there is an annual follow-up. At any time, these patients can be transferred to the full version of the register by entering the missing parameters. Patients for whom only the basic data is available (basic version) as well as patients with complete parameter profile in the register are kept in the same database and can be evaluated together. In general, no register-specific examinations will be carried out, but only parameters anyway recorded routinely.

Since this is a cohort study, no sample size calculation can be calculated. Evaluations are carried out continuously. The collective of the data should be described by descriptive statistics concerning the basic data as well as the data of the function diagnostics. Subentities of severe asthma should be identified by a cluster analysis.

03

Conditions studied

  • Severe Asthma

Keywords

  • Asthma
  • Severe
  • Register
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients presenting to participating study center (pulmonologists in private practice or in pulmonary departments in hospital within Switzerland)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In- and outpatients
  • Age ≥ 0 year
  • as documented by signature

Adults:

"Asthma which requires treatment with guidelines suggested medications for GINA steps 4-5 asthma:

  • High level therapy:

    1. high dose ICS with ≥ 1000 μg beclomethasone (powder) or equivalent in combination with LABA or leukotriene modifier/theophylline) for the previous year or
    2. Daily long-term therapy with systemic (CS) for ≥50% of the previous year to prevent it from becoming "uncontrolled" or which remains "uncontrolled" despite this therapy or
    3. Therapy with monoclonal antibodies independent from the co-therapy
  • Middle level therapy:

Protokollsynopsis SAR Version 01 16.01.2019 Seite 4/10 a) Daily long-term therapy with medium-to high-dose ICS (≥500 μg Beclomethason (powder) or equivalent in combination with LABA or leukotriene modifier/theophylline) for the previous year and uncontrolled asthma defined as at least one of the following:

  • Poor symptom control: ACQ consistently >1.5, ACT \<20 (or "not well controlled" by NAEPP/GINA guidelines).
  • Frequent severe exacerbations: two or more bursts of systemic CS (>3 days each) in the previous year.
  • Serious exacerbations: at least one hospitalization, ICU stay or mechanical ventilation in the previous year.
  • Airflow limitation: after appropriate bronchodilator withhold \<80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal).
  • Controlled asthma that worsens on tapering of these high doses of ICS or systemic CS (or additional biologics). The presence of any one of the following exclusion criteria will lead to exclusion of the patients:
  • Life-expectancy \<6 months
  • Insufficient knowledge of project language

Children:

The criteria for severe or difficult asthma in children and adolescents are considered fulfilled in the case of insufficient symptom control in the last year despite medium/high antiinflammatory long-term therapy:

  • age 0-18 years, at time of inclusion
  • diagnosis of bronchial asthma made by a physician
  • differential diagnoses excluded
  • good compliance and trained inhalation technique
  • treatment with biological approved for the treatment of severe asthma (currently only omalizumab) or

Proof of:

a) Positive Bronchodilation-test (≥12% increase in FEV1 after SABA) or b) Significant bronchial hyperresponsiveness after nonspecific provocation (e.g., with Methacholine or treadmill) according to ATS criteria (AJRCCM 2000)

  • High level of therapy:

    1. Prolonged therapy with high dose inhaled steroid (ICS) (> 400 μg Budesonide equivalent /> 200 μg fluticasone alone); or
    2. Daily long-term therapy with medium- to high-dose ICS (≥ 400 μg Budesonide equivalent / ≥200 μg fluticasone) in combination with long-acting betaagonists and / or leukotriene receptor antagonist and / or theophylline; or
    3. Therapy with oral steroids fixed ≥3 last months.
  • Insufficient asthma control

    a) Inadequate symptom control after NVL in the last 4 weeks: Protokollsynopsis SAR Version 01 16.01.2019 Seite 5/10

    • ≥3 x weekly asthma symptoms or use of ondemand medication; Or:
    • limited activity due to asthma; Or:
    • any symptoms at night; or b. Exacerbation(s) ≥1 last year that required treatment with systemic steroids and / or inpatient treatment c. limited lung function:
    • pathological Tiffeneau quotient or FEV1 at inclusion.
  • Submission of a written consent (parent/ legal guardian).

Exclusion criteria

Exclusion Criteria:

  • Life-expectancy \<6 months · Insufficient knowledge of project language
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Target follow-up
15 Years
Patient registry
Yes

Groups and cohorts

  • Severe Asthma

    All patients with severe asthma who will be treated in the participating centers should be continuously enrolled in the register.

06

What researchers measure

Primary outcomes

  1. Symptom Control

    Changes in symptom control at baseline and during the follow-up period and at study end using the Asthma Control Test (ACT).

    Time frame: Baseline, four months, yearly for up to 15 years

Secondary outcomes

  1. Exacerbations

    Number of exacerbation with/without hospitalization

    Time frame: Baseline, four months, yearly for up to 15 years

  2. Utilization of the health care system

    Number of Visits at one's general practitioner (GP) Number of Visits at a pneumologist/ specialist Number of emergency consultations Number of hospitalizations Number of rehabilitation stays

    Time frame: Baseline, four months, yearly for up to 15 years

  3. Quality of Life Questionnaire

    Mini Asthma Quality of Life Questionnaire(Mini-AQLQ) * 15 Questions, Scale 1 to 7 , Minimum Score 15, Maximum Score 105. * The higher the Score is, the better the quality of life

    Time frame: Baseline, four months, yearly for up to 15 years

  4. Symptoms and health-related quality of life

    Asthma Control Test 5 Questions, Scale 1- 5, Minimum score 5, max 25, the smaller the score the better is the Asthma control

    Time frame: Baseline, four months, yearly for up to 15 years

  5. Changes in Medication

    Changes in Medication will be monitored for each subject. Changes in dose in mg Changes in substances if there is a new drug used.

    Time frame: Baseline, four months, yearly for up to 15 years

  6. Forced Vital Capacity (FVC)

    Changes in FVC in liter and % from the target value

    Time frame: Baseline, after four months, and after 12 months, then every year up to 15 years

  7. Forced Exahled Volume in 1 second (FEV1)

    Changes in FEV1 in liter and % from the target value

    Time frame: Baseline, after four months, and after 12 months, then every year up to 15 years

  8. Tiffeneau Test

    Changes in Tiffeneau in % and % from Target Value

    Time frame: Baseline, after four months, and after 12 months, then every year up to 15 years

  9. Fraction of exhaled nitric oxide, FENO

    Changes in FENO in ppb

    Time frame: Baseline, after four months, and after 12 months, then every year up to 15 years

  10. Blood Gas Aanalysis

    pO2 in kPa/ mmHg pCO2 in kPa/ mmHg and Bloodoxygensaturation in %

    Time frame: Baseline, four months, yearly for up to 15 years

  11. Leucozytes

    Changes in Leucozytes in nl

    Time frame: Baseline, four months, yearly for up to 15 years

  12. Neutrophilic granulocytes

    in nl or %

    Time frame: Baseline, four months, yearly for up to 15 years

  13. Eosinophilic granulocytes

    in µl or %

    Time frame: Baseline, four months, yearly for up to 15 years

  14. Mortality

    Mortality rate due to severe Asthma

    Time frame: Baseline, four months, yearly for up to 15 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Feb 2034, 177 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 177 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2019
First posted
Jun 12, 2019
StartActual
May 13, 2019
Primary completionEst.
Feb 28, 2034
CompletionEst.
Feb 28, 2034
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (4 Switzerland)
  • Cantonal Hospital Baselland Liestal · Liestal, Switzerland
  • Hôpitaux Universitaires Genève · Geneva, Switzerland
  • Klinik für Pneumologie und Schlafmedizin, Kantonsspital St.Gallen · Sankt Gallen, Switzerland
  • Klinik für Pneumologie, Universitätsspital Zürich · Zurich, Switzerland
Show 4 removed
  • Cantonal Hospital Baselland Liestal · Liestal, Switzerland
  • Hôpitaux Universitaires Genève · Genf, Switzerland
  • Klinik für Pneumologie und Schlafmedizin, Kantonsspital St.Gallen · St.Gallen, Switzerland
  • Klinik für Pneumologie, Universitätsspital Zürich · Zürich, Switzerland
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    4 sites added, 4 sites removed
    Show 4 added (4 Switzerland)
    • Cantonal Hospital Baselland Liestal · Liestal, Switzerland
    • Hôpitaux Universitaires Genève · Geneva, Switzerland
    • Klinik für Pneumologie und Schlafmedizin, Kantonsspital St.Gallen · Sankt Gallen, Switzerland
    • Klinik für Pneumologie, Universitätsspital Zürich · Zurich, Switzerland
    Show 4 removed
    • Cantonal Hospital Baselland Liestal · Liestal, Switzerland
    • Hôpitaux Universitaires Genève · Genf, Switzerland
    • Klinik für Pneumologie und Schlafmedizin, Kantonsspital St.Gallen · St.Gallen, Switzerland
    • Klinik für Pneumologie, Universitätsspital Zürich · Zürich, Switzerland
    + 5 other changes: index terms, identifiers, verification date, responsible party and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03984253
Lead sponsor
Prof. Dr. Jörg Leuppi
Collaborators
AstraZeneca, GlaxoSmithKline, Lungenliga Schweiz, Novartis
Responsible party
Prof. Dr. Jörg Leuppi (Professor of Internal Medicine, Cantonal Hospital, Baselland) — Sponsor-investigator
First posted
Jun 12, 2019
Start date
May 13, 2019
Primary completion
Feb 28, 2034 (estimated)
Completion
Feb 28, 2034 (estimated)
Last update
Nov 2, 2026

Study contacts

Jörg Leuppi
Contact
Joerg.leuppi@ksbl.ch
+41619252181
Jörg Leuppi
principal investigator · Kantonsspital Baselland Liestal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion